Amarin Corp Plcuk (AMRN) Free Cash Flow (2010 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Free Cash Flow of $6.4 million for Q1 2026, up 151.27% YoY from $2.5 million in Q1 2025, and down 58.19% sequentially from $15.3 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Free Cash Flow (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Free Cash Flow across 17 years of filings, most recently posting $6.4 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 151.27% year-over-year to $6.4 million; the TTM figure through Mar 2026 stood at $25.6 million (up 182.83% YoY), while the FY2025 annual figure was $6.7 million, up 121.69% from the prior year.
- Free Cash Flow fell to $6.4 million in Q1 2026, from $15.3 million in the prior quarter.
- Over the last five years, Free Cash Flow for AMRN reached as high as $16.6 million in Q2 2025 and fell as low as -$98.8 million in Q1 2022.
- The 5-year median for Free Cash Flow is -$2.7 million (2024), against an average of -$11.2 million.
- Annual changes were most pronounced in 2024 — Free Cash Flow tumbled 1963.57% — and 2025, when it soared 704.07%.
- A 5-year view of Free Cash Flow shows it stood at $1.6 million in 2022, then tumbled by 141.56% to -$645000.0 in 2023, then plunged by 1963.57% to -$13.3 million in 2024, then jumped by 214.79% to $15.3 million in 2025, then slumped by 58.19% to $6.4 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered $6.4 million, $15.3 million, and -$12.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 3.01 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 1.47 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 3.56 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 547.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 2.93 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 1.48 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 2.43 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 2.18 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 346.00 Mn |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn | 6.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.39 Mn |
| Mar 31, 2026 | 6.39 Mn |
| Dec 31, 2025 | 15.28 Mn |
| Dec 31, 2025 | 15.28 Mn |
| Sep 30, 2025 | -12.70 Mn |
| Sep 30, 2025 | -12.70 Mn |
| Jun 30, 2025 | 16.61 Mn |
| Jun 30, 2025 | 16.61 Mn |
| Mar 31, 2025 | -12.46 Mn |
| Mar 31, 2025 | -12.46 Mn |
| Dec 31, 2024 | -13.31 Mn |
| Dec 31, 2024 | -13.31 Mn |
| Sep 30, 2024 | -2.36 Mn |
| Sep 30, 2024 | -2.36 Mn |
| Jun 30, 2024 | -2.75 Mn |
| Jun 30, 2024 | -2.75 Mn |
| Mar 31, 2024 | -12.60 Mn |
| Mar 31, 2024 | -12.60 Mn |
| Dec 31, 2023 | -645,000.00 |
| Dec 31, 2023 | -645,000.00 |